Regulatory Affairs and Regulatory Compliance
Regulatory affairs governs how a trial is authorized, conducted, and reported under the applicable framework. Candidates must know the ICH E6 Good Clinical Practice structure (principles, IRB/IEC, investigator, sponsor, protocol, investigator's brochure, essential documents), and how regional rules layer on top - for example, an IND in the US, a CTA in the EU under the Clinical Trials Regulation, and equivalent authorizations elsewhere.
Key concepts include regulatory submission pathways, clinical trial applications and amendments, investigator's brochure and reference safety information, annual reports and safety reports, essential documents and the trial master file, inspection readiness, and post-trial obligations such as clinical study reports and registry postings. Understand the difference between a substantial amendment (affects safety, rights, or scientific validity - requires approval before implementation) and a non-substantial amendment (administrative - often notification only).
Traps to watch: questions that conflate IRB/IEC approval with regulatory authority approval (both are usually required, and neither substitutes for the other); assuming a protocol deviation is automatically a violation; and forgetting that the reference safety information must be current for expectedness assessments. Another frequent trap is timing - implementation of changes generally requires prior approval except where needed to eliminate an immediate hazard.
Rule of thumb: if a change could affect subject safety, rights, or the reliability of results, treat it as substantial until proven otherwise.
Worked example: A sponsor wants to add a new secondary endpoint. Because it changes the scientific scope, it is a substantial amendment requiring approval before implementation, not a simple notification.